Abstract 3933
Background
Knowledge of molecular status improves the clinical benefit of targeted therapies. ALK rearrangement and EGFR/KRAS mutation are the main biomarkers tested to deliver or not targeted therapies in advanced NSCLC, but their economic impact has not been studied in large prospective cohorts. One objective of the IFCT-PREDICT.amm study was to evaluate the incremental cost-effectiveness ratio (ICER) of a strategy including the knowledge of at least one biomarker status at first- or second-line and the most appropriate treatment (intervention strategy) compared with the standard of care without biomarker testing (reference strategy).
Methods
A cost-effectiveness analysis was performed based on prospective individual data from 802 previously never treated French patients with advanced stage of NSCLC included between 01/2013 and 02/2014 in the IFCT-PREDICT.amm study. Overall survival (OS) during both first- and second-line and direct medical costs related to treatment, inpatient care and biomarker testing from the French payer perspective were valued. A propensity score matching was performed to compare patients with same baseline characteristics (n = 308). Probabilistic sensitivity analyses were performed to test the robustness of the results.
Results
A total of 647 patients received the intervention strategy. The incremental OS in the intervention strategy group was 6 months (p
Conclusions
Molecular testing before first- or second-line treatment initiation result in better survival with limited additional costs, validating it is a cost effective alternative in NSCLC management. These results can help decision maker to define conditions for appropriate diffusion of these technological innovations in general practices.
Clinical trial identification
Legal entity responsible for the study
N/A
Funding
INCa, Roche, Boeringher Ingelheim, Lilly
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Presenter: Leena Gandhi
Session: NSCLC, metastatic
Resources:
Abstract
Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Presenter: Leora Horn
Session: NSCLC, metastatic
Resources:
Abstract
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
Presenter: Vamsidhar Velcheti
Session: NSCLC, metastatic
Resources:
Abstract
Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Scott Antonia
Session: NSCLC, metastatic
Resources:
Abstract
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Presenter: Roy S. Herbst
Session: NSCLC, metastatic
Resources:
Abstract
Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
Presenter: Martin Reck
Session: NSCLC, metastatic
Resources:
Abstract
LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)
Presenter: Atsushi Horiike
Session: NSCLC, metastatic
Resources:
Abstract
Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)
Presenter: Balazs Halmos
Session: NSCLC, metastatic
Resources:
Abstract
Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
Presenter: Fabrice Barlesi
Session: NSCLC, metastatic
Resources:
Abstract
Invited discussant abstracts LBA48, 1215PD, 1216PD, 1217PD, and 1218PD
Presenter: Fiona Blackhall
Session: NSCLC, metastatic
Resources:
Presentation
Webcast